(NASDAQ: DRRX) Durect's forecast annual revenue growth rate of 42.51% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 8.21%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.95%.
Durect's revenue in 2024 is $8,321,000.On average, 3 Wall Street analysts forecast DRRX's revenue for 2024 to be $313,901,260, with the lowest DRRX revenue forecast at $226,587,481, and the highest DRRX revenue forecast at $472,108,985. On average, 1 Wall Street analysts forecast DRRX's revenue for 2025 to be $559,950,433, with the lowest DRRX revenue forecast at $559,950,433, and the highest DRRX revenue forecast at $559,950,433.
In 2026, DRRX is forecast to generate $734,081,361 in revenue, with the lowest revenue forecast at $734,081,361 and the highest revenue forecast at $734,081,361.